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Purpose: This study evaluated the treatment effectiveness and proper radiation dose of helical tomotherapy (HT) in spine 
oligometastases from gastrointestinal cancers.
Materials and Methods: From 2006 to 2010, 20 gastrointestinal cancer patients were treated with HT for spine 
oligometastases (31 spine lesions). The gross tumor volume (GTV) was the tumor evident from magnetic resonance imaging 
images fused with simulation computed tomography images. Clinical target volume (CTV) encompassed involved vertebral 
bodies or dorsal elements. We assumed that the planning target volume was equal to the CTV. We assessed local control rate 
after HT for 31 spine metastases. Pain response was scored by using a numeric pain intensity scale (NPIS, from 0 to 10).
Results: Spine metastatic lesions were treated with median dose of 40 Gy (range, 24 to 51 Gy) and median 5 Gy per 
fraction (range, 2.5 to 8 Gy) to GTV with median 8 fractions (range, 3 to 20 fraction). Median biologically equivalent dose 
(BED, α/β = 10 Gy) was 52 Gy10 (range, 37.5 to 76.8 Gy10) to GTV. Six month local control rate for spine metastasis was 90.3%. 
Overall infield failure rate was 15% and outfield failure rate was 75%. Most patients showed pain relief after HT (93.8%). 
Median local recurrence free survival was 3 months. BED over 57 Gy10 and oligometastases were identified as prognostic 
factors associated with improved local progression free survival (p = 0.012, p = 0.041).
Conclusion: HT was capable of delivering higher BED to metastatic lesions in close proximity of the spinal cord. Spine 
metastases from gastrointestinal tumors were sensitive to high dose radiation, and BED (α/β = 10 Gy) higher than 57 Gy10 
could improve local control.
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Introduction
Cancer cells most often reach the bones by hematogenous 
spread. This occurs predominantly at the axial skeleton more 
than the appendicular skeleton. The thoracic spine is the most 
commonly involved site in metastatic disease. Eighty percent 
of spinal metastases patients have spinal body metastasis 
[1]. Most patients with bone metastases were effectively 
treated with palliative irradiation in relieving pain. For pain 
management of bone metastasis, the most widely used 
palliative radiation therapy regimen is 30 Gy in 10 fractions 
[2]. Some reports have suggested that there are a considerable 
number of re-irradiation cases which have responded initially 
due to an insufficient radiotherapy dose. The commonly used 
palliative irradiation dose may be not enough to control 
spinal bone metastases from hepatocellular carcinoma or 
pancreatobiliary cancer [3].
  Stereotactic body radiotherapy (SBRT) uses hypofractionated 
radiation delivered to a precise target to maximize cell killing 
by implementation of high accuracy and reproducibility 
through image-guided radiotherapy (IGRT) [4]. SBRT is 
frequently used in the treatment of spinal metastases in 
addition to early stage non-small-cell-lung-cancer (NSCLC), 
hepatocellular carcinoma and pancreatic cancer etc [5,6]. 
Chang et al. [7] presented that SBRT could be safe and feasible 
when using a 30 Gy/5 fractions dose scheme. Ryu et al. [8] 
reported that the tolerance of the spinal cord is at least 10  Gy 
to 10% of the cord volume. Since then, the concept has been 
commonly used in spine SBRT.
  This study evaluated the local control rate after high dose 
radiotherapy by helical tomotherapy in spine oligometastases 
from gastrointestinal cancers and tried to find the proper 
radiation dose. We also tried to reveal whether improved local 
control would increase the local progression free survival (LPFS) 
rate and to evaluate secondarily the pain reduction rate of 
spinal metastasis after radiotherapy. 
Materials and Methods
1. Materials
From 2006 to 2010, 20 gastrointestinal cancer patients 
(11 hepatocellular carcinomas, 3 cholangiocarcinomas, 2 
pancreatic cancers, 2 stomach cancers, 1 colon cancer and 1 
rectal cancer) were treated with Helical Tomotherapy (HT, Hi-
Art system, Madison, WI, USA) for spine oligometastases at 
Yonsei Cancer Center, Severance Hospital. We retrospectively 
analyzed the results based on the clinical record. The patients’ 
ages ranged from 30 to 77 years (median, 60 years) and their 
characteristics are displayed on Table 1. Total spine lesions 
were 31 (median 1; range, 1 to 3). Involved spine levels in 
target volume were in total 78 (6 cervical, 42 thoracic, 24 
lumbar, and 6 sacrum). No patient had undergone any spine 
surgery before radiotherapy. We assessed local control rate 
and pain response for spinal metastasis lesions after HT and 
did not include intra-abdominal lesions of primary site in the 
treatment target. The Eastern Cooperative Oncology Group 
(ECOG) scale for performance status was ranged from 0 to 
3. In this study, patients with less than 5 metastases regions 
were 5 (25%). Five patients (25%) showed spinal cord lesions 
in imaging and one of them (5%) was re-irradiated due to a 
recurrence of the initial treatment lesions.
2. Therapeutic methods
Gross tumor volume (GTV) was defined as the volume of 
Table 1. Patient and characteristics
Characteristics No. (%)
Age (yr)
  Median (range)
  ≤60
  >60
Gender
  Male
  Female
Site of primary lesion
  Stomach
  Colon
  Rectum
  Pancreas
  Liver
Involved spine level
  Cervical
  Thoracic
  Lumbar
  Sacrum
ECOG performance status
  0
  1
  2
  3
Spinal tumor size (cm)
  ≤3
  >3
60 (30-77)
10 (50.0)
10 (50.0)
14 (70.0)
6 (30.0)
2 (10.0)
1 (5.0)
1 (5.0)
2 (10.0)
14 (70.0)
6 (7.7)
42 (53.8)
24 (30.8)
6 (7.7)
7 (35.0)
3 (15.0)
7 (35.0)
3 (15.0)
14 (45.2)
17 (54.8)
ECOG, Eastern Cooperative Oncology Group.
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lesions seen by magnetic resonance imaging (MRI) images 
fused with simulation computed tomography (CT) images. 
Clinical target volume (CTV) was defined differently according 
to the location of the cancer. If cancer is located on a 
pedicle, the CTV includes both the vertebral body and dorsal 
elements; if on spinous process, the CTV includes only dorsal 
elements; and if on vertebral body, the CTV includes only the 
corresponding vertebral body. The planning target volume (PTV) 
was set equal to the CTV. The spinal cord volume was drawn as 
the cord at the level of the CTV plus 5-6 mm above or below 
this region defined. If the tumor was small or if the total 
number of metastatic regions is less than 5, we augmented 
the fraction size. If the tumor was big or multiple, we reduced 
the fraction size and increased the number of fractions. The 
dose fraction scheme was converted to the 2 Gy/fraction (2-
Gy dose per fraction equivalent, α/β = 0.87 Gy). The 2-Gy dose 
per fraction equivalent total dose was less than the maximum 
tolerance dose in spinal cord (54 Gy) [9]. We assumed the dose 
constraint of the spinal cord to be at least 10 Gy to 10% of 
the cord volume if the dose per fraction exceeded 5 Gy. We 
additionally planned to prevent the occurrence of hot spots 
with the limitation to 20 Gy dose on the spinal cord. Spine 
metastatic lesions were treated with a median total dose of 40 
Gy (range, 24 to 51 Gy) and median fraction size of 5 Gy (range, 
2.5 to 8 Gy) to GTV and with median total dose of 28 Gy (range, 
15 to 42.5 Gy) and median fraction size of 3.25 Gy (range, 2 to 
6 Gy) to CTV. Median biological effective dose (BED, α/β = 10 
Gy) was 52 Gy10 (range, 37.5 to 76.8 Gy10) to GTV. Radiotherapy 
was performed with median 8 (range, 3 to 20) fractions. 
Pinnacle 6.0 (Phillips, Ditchburg, WI, USA) and Tomotherapy 
planning station (Hi-art System; Tomotherapy, Madison, WI, 
USA) were used for treatment. 
  During radiotherapy, a Head-neck-shoulder thermoplastic 
immobilized system (Type-S; Medtec, Alton, IA, USA) was 
used if the targets were cervical lesions and a BodyFix system 
(Medical Intelligence, Schwabmunchen, Germany) was used if 
the targets were thoracic, lumbar or sacral lesions in treatment 
planning and process. During Tomotherapy, radiotherapy was 
done after the correction everyday using megavoltage CT 
(MVCT) images that were fused with treatment-planning CT 
images.
3. Determination of treatment effectiveness
During treatment, we observed and assessed the process of the 
treatment through weekly meeting with patients. We followed 
up with the patients every month, every three months and 
every six months after the end of treatment and thereafter we 
followed up every six months. We defined the case as being 
more than a 20% increase in the initial size of the tumor to 
progressive disease on CT or MRI images after treatment. Local 
progression free survival was defined as the point of local 
progression after the end of radiotherapy.
  We measured the pain response (no pain, 0; worst pain 
imaginable, 10) scored by using a Numeric Pain Intensity 
Scale (NPIS, from 0 to 10). After Tomotherapy, if the pain 
was reduced to 0 we defined it as complete relief and if 
there was reduction of more than 3 points we defined it as 
partial relief. The opioid dose was compared with the opioid 
dose equivalence conversion table according to the standard 
National Comprehensive Cancer Network (NCCN) guidelines 
for adult cancer pain [10].
  Toxicity caused by radiotherapy was rated using the National 
Cancer Institute’s Common Terminology Criteria for Adverse 
Event (CTCAE) ver. 4.0 on a scale. 
  SPSS ver. 17 (SPSS Inc., Chicago, IL, USA) and the Kaplan-
Meier method, respectively, were used for statistical analysis 
and survival analysis. Logistic regression was used to find the 
correlation between the radiation dose and local control rate. 
To determine prognostic factors that govern survival, a log 
rank test was used for univariate analysis and Cox regression 
was used for multivariate analysis. 
Results
1. Treatment effect and treatment failure pattern
The median follow-up period of 20 patients was four months 
(range, 1 to 60 months). Within six months after treatment, 
there was local progression in 3 out of 31 treatment regions. 
Therefore, the local control rate was 90.3%. Within the follow-
up period (total 180 months), 3 patients out of 20 (15%) had 
infield disease progression and 15 patients (75%) had outfield 
disease progression. Infield and outfield treatment failure 
patients were 3 (15%). The most common distant metastasis 
regions were bone and lung (8 patients each).
  LPFS was 3 months (Fig. 1) in all patients. Progression 
free survival (PFS) was median 2 months and LPFS rate was 
27.8% for 6 months and LPFS was 22.2% for 1 year. The main 
treatment failure pattern was outfield failure. Success or 
failure rates of local control do not statistically significantly 
affect the PFS (p = 0.144) (Fig. 2). 
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2. Local failure analysis
Local failure was not observed in patients treated more than a 
57 Gy10 dose based on BED. Within 6 months, local recurrence 
was seen in the three infield patients. One of them was treated 
with 48 Gy10 and the others were treated with 56 Gy10 and all 
the three patients had spinal cord compression on imaging. 
3. Local progression free survival analysis
Univariate analysis was used to determine the prognostic 
factors governing the LPFS rate (Table 2). The patients were 
divided according to their ages, one group being those over 60 
and the other group younger than 60. There was no significant 
difference (p = 0.457) in the LPFS rate between the two groups. 
We confirmed that the primary site was not affected by the 
LPFS rate (p = 0.906) based on the primary tumor site. If there 
was a spinal cord compression, the LPFS rate tended to be 
lower (p = 0.088). Oligometastases with less than 5 metastasis 
regions had a significantly higher LPFS rate (p = 0.041) than 
non-oligometastases. We analyzed the infield tumor size 
with divided diameter by 3 cm. Compared to less than 3 cm, 
the tumor size of more than 3 cm had a higher statistically 
significant LPFS rate (p = 0.036). Whether the treatment 
region was single or multiple did not significantly affect the 
LPFS rate (p = 0.130). We divided the size of radiation dose 
per fraction at 5 Gy and analyzed the LPFS rate, but there was 
no significant difference (p = 0.438). A statistically significant 
higher LPFS rate (p = 0.012) (Fig. 3) was seen in the group of 
BED10 (≥57 Gy10) and this led to an increase in the disease-
free survival period (p = 0.048) (Fig. 4). There was no valuable 
prognostic factor in multivariate analysis (Table 3). 
4. Pain reduction
Of 16 patients experiencing pain, 15 had been given an opioid 
prior to treatment. When the opioid dose was compared with 
Fig. 1. Local progression free survival.
Fig. 2. Progression free survival according to local control. Three 
patients in local control (-) group and 17 patients in local control 
(+) group.
Table 2. Univariate analysis for prognostic factors
Variable
No. of 
patients (%)
LPFS 
(p-value)
Age (yr)
  ≤60
  >60
Primary cancer sites
  Liver
  Others
Spinal cord compression
  Yes
  No
No. of metastatic lesions 
  ≤5
  >5
Maximal tumor size (cm) 
  ≤3  
  >3 
Target multiplicity 
  Solitary
  Multiple
Fraction size (Gy)
  ≤5 
  >5  
BED10
a) (Gy10)
  ≤57 
  >57 
10 (50.0)
10 (50.0)
14 (70.0)
6 (30.0)
5 (25.0)
15 (75.0)
5 (25.0)
15 (75.0)
8 (40.0)
12 (60.0)
8 (40.0)
12 (60.0)
12 (60.0)
8 (40.0)
14 (70.0)
6 (30.0)
0.457
0.906
0.088
0.041
0.036
0.130 
0.438
0.012
LPFS, local progression free survival; BED, biological effective 
dose.  
a)Biological effective dose α/β = 10 Gy. 
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the opioid equivalence conversion table according to the 
standard NCCN guidelines for adult cancer pain [10], 3 of the 
patients (20%) were opioid-free, 6 (40%) used a lower dose 
than at pre-treatment, 4 (26.7%) used the same dose as pre-
treatment, and 2 (13.3%) began using or used more opioid. All 
16 patients with pain (NPIS median 7) showed pain reduction, 
4 (25%) showed complete pain relief, and 12 (75%) showed 
partial pain relief. The median value of pain reduction was 
NPIS five. Pain reduction effects were observed within two 
months after treatment in 14 patients except two.
5. Treatment-related toxicity
Due to acute toxicity, there was one CTCAE grade 1 anorexia 
patient and two CTCAE grade 1 vomiting patients. After one 
month of treatment herpes zoster had occurred in one patient. 
No chronic toxicity was observed. No patient had radiation-
induced spinal cord complications after treatment. 
Discussion and Conclusion
The recent development of radiotherapy equipment has 
facilitated the application of hypofractionated radiotherapy 
and attempts to determine proper treatment volumes and 
radiation doses are underway in various organizations [11-
13]. In palliative radiation therapy of spinal metastases, with 
conventional external beam therapy, the treatment volume 
usually encompasses one normal vertebra above and below 
the metastatic lesions. But high-dose hypofractionated IMRT 
on spinal metastases has a narrower treatment volume than 
the existing volume. Despite our treating only the spine with 
metastastatic lesions defined as PTV in this study, there was 
no patient with treatment failure around the spine above or 
below one level of target lesions during the follow-up period. 
It seems appropriate that the target is limited only to the spine 
with metastasis lesions. 
  When SBRT is used on spinal metastasis, to determine the 
treatment volume and radiation dose we have to consider the 
following factors: histological findings, the extent or number 
of involved spinal lesions, the progress of the cancer and the 
shape and size of the tumor. If the radiation dose per fraction 
is higher, the dose on the spinal cord should be carefully 
limited [14]. A lesion near the spinal cord is necessary to 
increase radiation dose in a safe method, paying attention to 
the tolerance dose. We could consider using high-precision 
radiotherapy equipment like Tomotherapy in this case [6]. 
Tomotherapy could allow a steep dose gradient (10% dose 
reduction per 1 mm) and protect the spinal cord within a few 
millimeters of the target. 
Fig. 3. Local progression free survival rate according to biological 
effective dose (BED10 57 Gy10) of the Tomotherapy. Six patients in 
BED10 > 57 Gy10 group and 14 patients in BED10 ≤ 57 Gy10 group.
Table 3. Multivariate analysis for prognostic factors
Variable
Hazard 
ratio
95% CI
LPFS 
(p-value)
No. of metastatic lesions 
  (≤5, >5)
Maximal tumor size (cm)
  (≤3, >3)
BED10 (Gy10)
a) (≤57, >57)
0.760
3.236
0.230
0.148-3.907
0.894-11.712
0.049-1.073
0.743
0.074
0.062
CI, confidence interval; LPFS, local progression free survival; 
BED, biological effective dose. 
a)Biological effective dose α/β = 10 Gy. 
Fig. 4. Progression free survival rate according to biological 
effective dose (BED10 57 Gy10) of the Tomotherapy. Six patients in 
BED10 > 57 Gy10 group and 14 patients in BED10 ≤ 57 Gy10 group.
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  Tomotherapy is a type of IMRT. It is similar to a helical CT 
scanner in the rotation of its accelerator and gantry while the 
patient is moved through a donut-shaped gap and it can treat 
multiple lesions simultaneously at an average of 10.7 minutes 
within a short time [15,16]. Also, the tumor can be treated 
even if it is located within 5 mm of the spinal cord because 
pre-treatment MVCT can reproduce the patient positioning 
and  can deliver radiation exactly [6,14]. Mahan et al. [17] rep-
orted that re-irradiation was successfully performed by HT in 
spinal metastasis patients with local recurrence and HT was 
able to maintain a setup error within 1.2 mm without the use 
of special stereotactic immobilization.
  Recently, interest in oligometastases has been increasing. 
Though oligometastases is a form of distant metastatic 
progression, it has been shown that the progress of the tumor 
in the metastatic region can be prevented or delayed by active 
local treatment such as surgery or radiotherapy. This is known 
to improve the survival rate ultimately through improved 
local control in this state [18]. Higher BED hypofractionated 
radiotherapy in oligometastases has been attempted. Milano 
et al. [19,20] announced that the local control rate and 
the survival rate were improved when hypofractionated 
radiotherapy was performed in limited metastases (defined 
as five lesions or fewer). Inoue et al. [21] also reported that 
the 3-year local control rate increased up to 80% after SBRT 
to oligometastases. Our center commonly uses the 24 Gy/3 
fractions dose that is regarded as safe considering the spinal 
cord tolerable dose [9] when we treat patients with spinal 
metastases by Tomotherapy. This is equivalent to 33 Gy/11 
fractions corresponding palliative radiation therapy if it is 
converted to BED (α/β = 10 Gy). If we used this dose scheme, 
the local control rate was quite low by 39% according to 
the results of previous studies. Dose increment would be 
needed for oligometastases patients who may have survival 
improvement by local control [18,20].
  After radiotherapy, it was reported that bone metastases 
of gastrointestinal cancers showed response rates similar to 
those of bone metastases from other primary cancers [22]. 
According to the study of Milano et al. [19], a 4-year 73% 
high local control rate was seen when 50 Gy/10 fractions was 
used for treatment of oligometastases. Among gastrointestinal 
cancers, pancreatobilliary cancer or hepatocellular cancer 
was reported to have a respectively lower local control rate 
compared to other primary cancers [23]. Other research has 
shown that image response and pain reduction increased by 
the use of high-dose radiotherapy (39 Gy10) on hepatocellular 
cancer [24]. 
  In this study, radiation dose was a factor that affected local 
control. The 24 Gy/ 3 fractions dose commonly used in spinal 
metastases is equivalent to 43.2 Gy10 if it is converted to BED 
(α /β  = 10 Gy) and this dose is also equivalent to 30 Gy/5 
fractions, 33 Gy/11 fractions and 36 Gy/18 fractions. This is not 
a curative-intention therapy but rather a palliative treatment 
radiation therapy. 
  All three patients who failed the 6 month-based local control 
have spinal cord compression on imaging and were treated 
with BED 48 Gy10 or 56 Gy10. They had complained of motor 
weakness before radiation therapy. These patients had larger-
sized tumors inside the spinal canal after treatment. One of 
them with worsened symptom showed paraplegia at the end 
of treatment. The patient already had grade III motor weakness 
before treatment. Radiation therapy seemed to be unable to 
prevent the worsening of neurological symptoms because the 
symptoms were already present from the start of treatment. 
The local control rate with spinal cord compression seemed 
to be worse than others. For these patients, respectively lower 
dose, thought to be safe, was selected due to the dose limit 
to adjacent damageable organs, i.e. the spinal cord. It seemed 
not to be an effective dose to local control of the tumor. 
When the life expectancy of patients is less than 6 months, 
the improvement of the local control rate by radiation exceeds 
the dose limit of the spinal cord because the spinal cord is 
a late responding organ. However, if the patients survive 
beyond their life expectancy, a very small number of patients 
may have the risk of severe side effects like radiation myelitis. 
Therefore, surgery or other methods of therapy than SBRT 
should be considered as a priority to patients with spinal cord 
compression. One of the local failure patients received re-
irradiation due to the recurrence of the same lesions. When 
radiation therapy was used as a conventional treatment, a 
total dose of 38 Gy (initial dose of 5 Gy in 2 fractions followed 
by the dose of 33 Gy in 11 fractions) was irradiated and after 
9 months 30 Gy (5 Gy dose per fraction) was re-irradiated 
by Tomotherapy and the maximum radiation dose for the 
spinal cord was limited to less than a total of 20 Gy dose. Re-
irradiation data in animals and humans shows that partial 
repair of radiotherapy (RT)-induced sub-clinical damage 
becomes evident about 6 months after RT and increases over 
the next 2 years [9]. This patient had no post–RT side effects 
and showed tumor size increment of irradiated lesion after 
3 months of RT. It may be thought that it didn’t respond to 
treatment because radiation-resistant cells were redistributed 
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[25,26].
  Of the patients studied, two patients with hepatocellular 
oligometastases and currently with no recurrence or 
metastases were in successful local control after treatment. 
The size of tumors was small and all lesions were included in 
the treatment area. The patients were treated using 48 Gy/8 
fractions (α/β =10 Gy, BED 76.8 Gy10) of high-dose radiation 
(Fig. 5). We knew that the 50 Gy/10 fraction dose used in the 
Milano et al. [19]'s study with a 2-year 77% local control rate 
was equal to 48 Gy/8 fractions (BED 75 Gy10). It was a high 
dose also equivalent to 64 Gy/32 fractions (2 Gy per fraction). 
These patients showed additional metastases lesions outside 
the treatment range, but they could be controlled by pertinent 
treatment. We observed that after radiation, soft-tissue 
metastases were reduced in size and re-calcified by observation 
with position emission tomography-computed tomography 
(PET-CT) images. High-dose radiation to hepatocellular 
metastases resulted in excellent treatment results [24]. 
Oligometastases needs to be treated aggressively. In addition, 
the use of radiation dose escalation and hypofractionated dose 
in SBRT should be primarily considered. 
  The results of this study have shown that there was a 
difference in the local control rate by 3 cm based on the 
maximum tumor diameter and that the larger size of the 
tumor does not respond to radiation therapy. This was also 
shown by Milano et al. [19,20].
  It seems that young patients have strong cancer-resistant 
immune systems [27] and need more active treatment. 
However, the age of patients was not a significant factor 
[28] affecting the grade of palliative radiation therapy on 
bone metastases not only in prior research results but also in 
additional analysis of this study. 
  In this study, all 16 patients with pain in the spinal metastases 
region experienced pain relief after treatment. Because two of 
them took more opioid analgesics after treatment, it is difficult 
to say that all patients had effective pain relief. This means 
that only 14 patients (87.5%) experienced a pain relief effect. 
  The pain caused by bone metastases occurs mainly by 
metamorphosis of the periosteum with its multitude of nerves 
[29] and the pain caused by an unstable spine was known 
to be around 10%. The determination of a spinal instability 
was based on clinical judgment, taking the following factors 
into account: 1) extent of spine collapse; 2) presence of spine 
deformity; 3) involvement of all three columns of the spine; 
4) severe mechanical pain [30]. Pain associated with a spinal 
instability did not respond well to radiation therapy [31]. 
There was no statistically significant correlation between pain 
response and local control (Pearson’s χ2 test, p = 0.751) in this 
study. Pain was influenced by the site and the shape of the 
spinal metastases regions and was controlled by respectively 
lower doses than the required dose for local control and the 
response for radiotherapy seemed to be favorable [32].
  This study was a retrospective analysis and its treatment 
methods were inconsistent and might have a selection bias. 
Analysis for prognostic factors was unreliable due to the low 
number of patients (20). In addition, due to the lack of survival 
time for most of the patients, the short follow-up period was 
a limitation to analysis. For clearer results, a large number of 
Fig. 5. Illustration of a patient case with hepatocellular carcinoma multiple metastasis in the L1 vertebra body. Positron emission 
tomography-computed tomography (PET-CT) before Tomotherapy showed hypermetabolic lesion in L1 (A). Prescriptive radiation dose to 
gross tumor volume (GTV) and clinical target volume (CTV) were 48 Gy and 24 Gy with 8 fractions, respectively (B). On 6 months after 
Tomotherapy, there was no viable tumor lesion on previous tumor site in PET-CT (C).
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prospective clinical studies are required. 
  In conclusion, if high-dose Tomotherapy (≥BED 57 Gy10) is 
applied to spinal oligometastases, less than 3 cm and free of 
spinal cord compression by hypofractionated radiotherapy, 
there can be a successful local control rate and extension of 
the LPFS period.
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